Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment - 20/05/22
Doi : 10.1016/j.jinf.2022.03.022
Jin Gu Yoon a, 1, Jin Sae Yoo b, 1, Jungmin Lee c, Hak-Jun Hyun a, Hye Seong a, Ji Yun Noh a, Hee Jin Cheong a, Woo Joo Kim a, Young Rong Kim b, Jung Yeon Heo b, Joon-Yong Bae c, Chunguang Cui c, Sohyun Lee c, Man-Seong Park c, 1, ⁎ 
, Joon Young Song a, 1, ⁎
, Joon Young Song a, 1, ⁎ a Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
b Department of Infectious Diseases, Ajou University School of Medicine, Suwon, South Korea
c Department of Microbiology, Biosafety Center, College of Medicine, Institute for Viral Diseases, Korea University, Seoul 02841, South Korea
⁎Corresponding authors.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | The cycle threshold (Ct) value of RT-PCR was not significantly reduced by remdesivir. |
• | Infectious virus was not detected after the third dose of remdesivir despite dexamethasone treatment. |
• | SARS-CoV-2 shedding significantly decreased after remdesivir treatment, regardless of the Ct value. |
• | Rapid antigen test is a viable adjunctive tool that guides the decision to terminate the isolation. |
Plan
© 2022
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 84 - N° 6
P. 834-872 - juin 2022 Retour au numéro
Article précédent
- Interferon-induced transmembrane protein 3 gene polymorphisms are associated with COVID-19 susceptibility and severity: A meta-analysis
- Yapeng Li, Lanlan Wei, Lanye He, Jiahui Sun, Nanyang Liu
- Multiplex PCR rapid testing for meningitis/encephalitis
- Yu-Chuan Tseng, Peter Bor-Chian Lin, Chiung-Tzu Hsiao, Po-Ren Hsueh
Bienvenue sur EM-consulte, la référence des professionnels de santé.